Neuren Pharmaceuticals Limited (NURPF)
| Previous close | 14.00 |
| Open | 13.56 |
| Bid | 12.63 x 0 |
| Ask | 13.18 x 0 |
| Day's range | 14.00 - 14.00 |
| 52-week range | 6.17 - 17.20 |
| Volume | |
| Avg. volume | 210 |
| Market cap | 1.867B |
| Beta (5Y monthly) | 2.03 |
| PE ratio (TTM) | 17.50 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Neuren Phase 2 trial shows significant improvements in Pitt Hopkins syndrome
Neuren Pharmaceuticals (ASX: NEU) today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Pitt Hopkins syndrome (PTHS). Statistically significant improvement from baseline was observed by both clinicians and caregivers from treatment, across all 4 efficacy measures that were specifically designed to assess the core characteristics of PTHS. There are no approved treatments for PTHS despite its severely debilitating impact on the lives of patients, as well as
- PR Newswire
Neuren Phase 2 trial shows significant improvements in Phelan-McDermid syndrome
Neuren Pharmaceuticals (ASX: NEU) today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Phelan-McDermid syndrome (PMS). Significant improvement was observed by both clinicians and caregivers from treatment, across multiple efficacy measures. Improvements were consistently seen across many of the core PMS characteristics. PMS has severe quality of life impacts for those living with the syndrome, as well as parents and siblings. There are no approved treatme
